Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.
BACKGROUND
Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient-reported outcome measures remain scarce.


OBJECTIVE
To investigate satisfaction with medication, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) for biologics in daily practice psoriasis care in the first 6 months of treatment; and to identify possible differences in satisfaction with medication between patients experienced (biologics-experienced) and inexperienced (biologics-inexperienced) in the use of biologics.


METHODS
TSQM baseline measurements were compared using measurements taken after 6 months, using the Wilcoxon signed-rank test for paired comparisons. Intention-to-treat with last observation carried forward (ITT with LOCF) and as-treated analyses were performed. The difference between biologics-experienced and biologics-inexperienced patients for TSQM was analysed using ITT with LOCF. At 6 months, outcomes for biologics-experienced and biologics-inexperienced patients were compared using the Mann-Whitney U-test.


RESULTS
One hundred and six patients were eligible for analysis, and treated with etanercept (n = 34), adalimumab (n = 49) or ustekinumab (n = 23). Fifty-four per cent of patients were biologics-inexperienced. A statistically significant improvement was seen in all domains of the TSQM ('effectiveness', 'side-effects', 'convenience' and 'global satisfaction') by comparison of months 3 or 6 with baseline (all P ≤ 0·02). After 6 months, biologics-inexperienced patients scored better on the 'global satisfaction' domain than biologics-experienced patients (P < 0·01).


CONCLUSIONS
We provide a prospective, longitudinal analysis of TSQM for biologics in daily practice psoriasis care. High satisfaction rates were achieved. The 'effectiveness' and 'convenience' domains showed the most room for improvement.
Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
J M P A
JM
van den Reek
P P M
PP
van Lüumig
M E
ME
Otero
J
J
Zweegers
P C M
PC
van de Kerkhof
P M
PM
Ossenkoppele
M D
MD
Njoo
J M
JM
Mommers
M I A
MI
Koetsier
W P
WP
Arnold
B A M
BA
Sybrandy-Fleuren
A L A
AL
Kuijpers
M P M
MP
Andriessen
M M B
MM
Seyger
W
W
Kievit
E M G J
EM
de Jong
D001685:Biological Factors / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D012042:Registries; D016896:Treatment Outcome
D001685:Biological Factors; D001688:Biological Products; D003879:Dermatologic Agents